Positive data announced from the pivotal part 2 of the SUNFISH trial that evaluated the safety and efficacy of risdiplam in adult and pediatric patients with Type 2 or Type 3 SMA.
The FDA has granted Fast Track designation to neflamapimod (EIP Pharma) for the treatment of dementia with Lewy bodies (DLB).
Clariscan is a macrocyclic, gadolinium-based contrast agent, for intravenous use with magnetic resonance imaging in brain (intracranial), spine and associated tissues in adult and pediatric patients.
The Food and Drug Administration (FDA) has placed a partial hold on clinical trials for the intrathecal administration of AVXS-101 (AveXis, a Novartis Company) in patients with spinal muscular atrophy (SMA) Type 2.
Vumerity (diroximel fumarate; Biogen) has been approved for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.
The Warnings and Precautions section has been updated to address the potential for late-onset neurotoxicity, including ataxia and encephalopathy with efavirenz treatment.
Company claimed their CBD products can be used to treat a variety of conditions and diseases including teething pain and earaches in infants, skin problems, autism, ADHD, Parkinson disease, and Alzheimer disease, among others.
BoNT-A showed significant improvements in the frequency and severity of photophobia and eye discomfort.
Based on results from the phase 1/2 trial, FX-322 was found to be safe and well-tolerated with no serious adverse events.
The Food and Drug Administration has expanded the indication of abobotulinumtoxinA to include the treatment of upper limb spasticity in patients aged 2 years and older.
